Duyuru • Jun 05
MindBio Therapeutics Corp. Launches Intox AI for Validation and Testing MindBio Therapeutics Corp. has launched its lead commercial software Intox AI for validation and testing. MindBio’s enterprise solution for intoxication and fatigue detection, Intox AI enables new analytical capabilities to detect Cocaine, Cannabis, Alcohol, Psychedelics, Narcotic use and human fatigue from voice. Intox AI is a category changer in drug use and fatigue detection in high-risk industries where sobriety and alertness is an essential health and safety requirement that saves lives. The technology will be deployed to the Edge AI Kiosks that are due for initial prototype manufacturing completion shortly. The Company is targeting industries for commercialisation that have pressure to scale up drug and alcohol testing and where testing is mandated by regulators, such as the mining industry, aviation and construction, heavy transport, law enforcement and where high volume testing at scale for a variety of drugs and alcohol and human fatigue presents major challenges for management. The current systems for drug and alcohol testing involve a mouth swab test and breathalyser. These tests are time consuming, costly on a per test basis, unhygienic and environmentally harmful due to the quantity of plastic use and waste disposal. MindBio’s Voice AI solution aims to provide quick scanning for intoxication and removes these problems from legacy drug testing procedures. MindBio’s solution aims to deliver enhanced efficiency and testing at scale, not possible with current systems. The Company is on track to deliver its first prototype testing kiosks shortly and is delighted the core software is ready for testing and validation. Duyuru • May 11
MindBio Therapeutics Corp Develops Fatigue Prediction Model Using Speech Analytics And AI MindBio Therapeutics Corp. commercializing AI-driven voice analytics for drug and alcohol intoxication detection, has developed a fatigue recognition and detection technology using an analysis of voice and the Company’s proprietary AI. The fatigue module will be added to the Company’s Edge AI Intoxication Detection Kiosks as an add on commercial feature designed to predict and detect fatigue in high risk industries such as aviation, road transport and mining, where sobriety and alertness is paramount to safety. In a world first claim by the Company, in its recent patent application titled “Detection of Neurologically Active Substances and Fatigue in a Human by Analysis of Voice Characteristics”, the technology aims to predict intoxication from a range of substances plus fatigue, in an add on to the Company’s anticipated commercial offering which is on track for initial commercial testing in late Second Quarter, 2026. The technology processes human voice audio signals using a short sentence or pangram to identify an individual potentially affected by a neurologically active substance, or by fatigue. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. Duyuru • May 07
MindBio Therapeutics Corp. Develops Cross-Language AI Speech Analytics Capability for Intoxication Detection MindBio Therapeutics Corp. announced the Company has developed a cross-language speech model for the detection of drug and alcohol intoxication. The language agnostic model is a game changer for the non-invasive detection of a range of neurologically active substances from a voice recording across cultures and languages. The technology being developed by MindBio is a game changer for intoxication detection where drug and alcohol testing is mandated by regulators, such as the mining industry, aviation and construction and where high volume testing at scale for a variety of drugs and alcohol presents major challenges for management, is time consuming, physically invasive and expensive. MindBio has developed an AI model currently being integrated into an Edge AI touchscreen kiosk, that can detect a range of neurologically active substances that impair cognition and performance. The technology is a game changer for the scalable detection of substance use in workplace health, safety and law enforcement. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. Duyuru • May 01
MindBio Therapeutics Corp Files Patent Applications For Voice and AI Drug and Alcohol Intoxication Detection Technology MindBio Therapeutics Corp. had filed patent applications for its technology that uses voice and AI to detect intoxication. The technology developed by MindBio is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and in law enforcement where high-volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. In a world first, MindBio has developed an AI model that powers its Edge AI Intoxication Detection Kiosks, using over 50 million data points to predict drug and alcohol intoxication with remarkable reliability and accuracy, just by using the human voice. The Company’s novel discoveries that have led to its patent application filings, allow it to use its prediction technology to detect a range of substances that effect the central nervous system and human cognition and performance. The Company also announced that it is on track for the delivery of its hardware and software solution, an Edge AI touchscreen kiosk for commercial testing, specifically for the mining and aviation industries by the end of Second Quarter, 2026. MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for the detection of drug and alcohol intoxication using the human voice and AI in a range of enterprise environments including the mining industry, aviation, construction and law enforcement. Duyuru • Apr 14
MindBio Therapeutics Corp. Deploys New Technology Intox Collect And Expands CNS Drug Detection Capabilities With Voice And Facial Recognition MindBio Therapeutics Corp. had completed the development of new technology Intox Collect which has enabled the Company to rapidly scale its collection and analysis of data samples (including voice and facial recognition data) from a wide range of substances when consumed. Intox Collect is a novel software which has enhanced the Company’s data collection, testing and analytical capabilities for a range of stimulants and depressants of the human central nervous system. In a world first, MindBio has developed an AI model that uses over 50 million data points, (with that number expected to triple in the coming months) to predict drug and alcohol intoxication with remarkable accuracy, just by using the human voice. The completion of the Company’s new Intox Collect™ software allows the company to expand its prediction technology to a range of substances that effect the central nervous system, which when consumed impair cognition and human performance. The technology is a game changer for intoxication detection, particularly where drug and alcohol testing is mandated by regulators, such as the mining, aviation and construction industries and where high volume testing at scale for a variety of drugs and alcohol presents major challenges, is time consuming, physically invasive and expensive. The Company recently announced that a prototype design for its new Edge AI Hardware-Software solution is nearing completion and its kiosk touch screen devices will be ready for testing late in the Second Quarter, 2026. Duyuru • Apr 03
MindBio Therapeutics Corp. announced that it has received CAD 1.437829 million in funding On April 1, 2026, MindBio Therapeutics Corp closed the transaction. The company announced that it has issued 2,396,381 units at a price of CAD 0.60 per Unit for gross proceeds of 1,437,828.87. In connection with completion of the Offering, the Company paid aggregate cash fees of CAD 70,183.97 and issued an aggregate of 116,973 non-transferable Share purchase warrants to eligible third-parties who introduced subscribers to the Offering. Each Finder Warrant entitles the holder thereof to acquire one Share at a price of CAD 0.80 for a period of thirty-six months after the date of issue, subject to accelerated expiry in the event the closing price of the Shares on the CSE exceeds $1.00 for ten consecutive trading days. All securities issued in connection with the Offering are subject to restrictions on resale for a period of four months-and-one-day in accordance with applicable securities laws. The Offering remains subject to final regulatory approvals. 
